Scavenger receptor-AI targeted theranostic nanoparticles for regression of atherosclerotic plaques via ABCA1 modulation

被引：5

作者：

Zhu, Yan ^{[1
,3
]}

Xu, Yanni ^{[2
]}

Han, Dong ^{[3
]}

Zhang, Xiujin ^{[3
]}

Qin, Cheng ^{[3
]}

Liu, Jing ^{[3
]}

Tian, Lei ^{[3
]}

Xu, Mengqi ^{[3
]}

Fang, Yan ^{[3
]}

Zhang, Yang ^{[3
]}

Wang, Yabin ^{[3
]}

Cao, Feng ^{[1
,3
]}

机构：

[1] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll CAMS, Inst Med Biotechnol, Natl Ctr Screening Novel Microbial Drugs, NHC Key Lab Biotechnol Antibiot, 1 Tiantan Xili, Beijing 100050, Peoples R China

[3] Chinese Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Geriatr Dis, Med Ctr 2, Dept Geriatr Cardiol, Beijing 100853, Peoples R China

来源：

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE | 2023年 / 50卷

基金：

中国国家自然科学基金;

关键词：

Nanoparticle; ATP-binding cassette transporter A1; Scavenger receptor-AI; Atherosclerosis; CHOLESTEROL EFFLUX; DELIVERY SYSTEM; THERAPY; DYSFUNCTION; PROGRESSION; METASTASIS; DISEASE; CANCER;

D O I：

10.1016/j.nano.2023.102672

中图分类号：

TB3 [工程材料学];

学科分类号：

0805 ; 080502 ;

摘要：

ATP-binding cassette transporter A1 (ABCA1) plays a crucial role in atherosclerotic formation through mediated cholesterol efflux in macrophage-derived foam cells. In this study, a scavenger receptors AI (SR-AI) targeted theranostic nanoparticles was constructed for atherosclerosis regression via ABCA1 activation in foam cells. ABCA1-upregulator 5242331 and IR780 were encapsulated in PLGA-PEG micelles which were conjugated with SR-AI targeting peptide (PP1) to formulate the nanoparticles (SAU-NPs). Immunostaining revealed that SR-AI was highly expressed both in macrophage foam cells and in atherosclerotic plaque of ApoE-/- mice. The SAU-NPs have shown more active targeting to plaque lesion with higher stability compared with non-SR-AI targeted nanoparticles. The transformation from macrophage to foam cells was inhibited by SAU-NPs carried 5242331. Cholesterol deposition was effectively reduced in foam cells by SAU-NPs through activating the LXR & alpha;-ABCA1/ABCG1/SR-BI pathway. In conclusion, theranostic SAU-NPs which carried ABCA1-upregulator 5242331 exert beneficial effects on atherosclerosis regression via LXR & alpha; activation. & COPY; 2023 Published by Elsevier Inc.

引用

页数：16

共 56 条

[1] Mechanistic/mammalian target of rapamycin: Recent pathological aspects and inhibitors [J].

Abdel-Maksoud, Mohammed S. ;

El-Gamal, Mohammed I. ;

Benhalilou, Dalia Reyane ;

Ashraf, Sandy ;

Mohammed, Shatha Abdulghaffar ;

Oh, Chang-Hyun .

MEDICINAL RESEARCH REVIEWS, 2019, 39 (02) :631-664

[2] Lipoproteins in Atherosclerosis Process [J].

Arnao, Valentina ;

Tuttolomondo, Antonino ;

Daidone, Mario ;

Pinto, Antonio .

CURRENT MEDICINAL CHEMISTRY, 2019, 26 (09) :1525-1543

[3] High-Density Lipoprotein-Mediated Anti-Atherosclerotic and Endothelial-Protective Effects: A Potential Novel Therapeutic Target in Cardiovascular Disease [J].

Besler, Christian ;

Heinrich, Kathrin ;

Riwanto, Meliana ;

Luescher, Thomas F. ;

Landmesser, Ulf .

CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (13) :1480-1493

[4] Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis [J].

Chen, Jun ;

Zhang, Xixi ;

Millican, Reid ;

Sherwood, Jennifer ;

Martin, Sean ;

Jo, Hanjoong ;

Yoon, Young-sup ;

Brott, Brigitta C. ;

Jun, Ho-Wook .

ADVANCED DRUG DELIVERY REVIEWS, 2021, 170 :142-199

[5] Molecular mechanisms for ABCA1-mediated cholesterol efflux [J].

Chen, Lei ;

Zhao, Zhen-Wang ;

Zeng, Peng-Hui ;

Zhou, Ying-Jie ;

Yin, Wen-Jun .

CELL CYCLE, 2022, 21 (11) :1121-1139

[6] Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis [J].

Chen, Wei ;

Schilperoort, Maaike ;

Cao, Yihai ;

Shi, Jinjun ;

Tabas, Ira ;

Tao, Wei .

NATURE REVIEWS CARDIOLOGY, 2022, 19 (04) :228-249

[7] Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials [J].

Fulcher, Jordan ;

O'Connell, Rachel ;

Voysey, Merryn ;

Emberson, Jonathan ;

Blackwell, Lisa ;

Mihaylova, Borislava ;

Simes, John ;

Collins, Rory ;

Kirby, Adrienne ;

Colhoun, Helen ;

Braunwald, Eugene ;

La Rosa, John ;

Pedersen, T. R. ;

Tonkin, Andrew ;

Davis, Barry ;

Sleight, Peter ;

Franzosi, Maria Grazia ;

Baigent, Colin ;

Keech, Anthony ;

de Lemos, J. ;

Blazing, M. ;

Murphy, S. ;

Downs, J. R. ;

Gotto, A. ;

Clearfield, M. ;

Holdaas, H. ;

Gordon, D. ;

Koren, M. ;

Dahloef, B. ;

Poulter, N. ;

Sever, P. ;

Knopp, R. H. ;

Fellstroem, B. ;

Holdaas, H. ;

Jardine, A. ;

Schmieder, R. ;

Zannad, F. ;

Goldbourt, U. ;

Kaplinsky, E. ;

Colhoun, H. M. ;

Betteridge, D. J. ;

Durrington, P. N. ;

Hitman, G. A. ;

Fuller, J. ;

Neil, A. ;

Wanner, C. ;

Krane, V. ;

Sacks, F. ;

Moye, L. ;

Pfeffer, M. .

LANCET, 2015, 385 (9976) :1397-1405

[8] Targeted Strategy in Lipid-Lowering Therapy [J].

Dayar, Ezgi ;

Pechanova, Olga .

BIOMEDICINES, 2022, 10 (05)

[9] Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis [J].

Di Pietro, Natalia ;

Formoso, Gloria ;

Pandolfi, Assunta .

VASCULAR PHARMACOLOGY, 2016, 84 :1-7

[10] Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR [J].

Dong, Bin ;

Singh, Amar B. ;

Guo, Grace L. ;

Young, Mark ;

Liu, Jingwen .

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2019, 43 (05) :1927-1938

← 1 2 3 4 5 6 →